🧬

Thymalin

Thymalin is a polypeptide extract from calf thymus, developed in Russia in the 1970s by Vladimir Khavinson and Vyacheslav Morozov, and approved there as a prescription immunocorrector in 1982. Most people take it for one reason: to push back against the age-related decline of the thymus, the gland that trains your T-cells and starts shrinking from puberty onwards. By 60-70 it's largely fat, your output of new T-cells has collapsed, and your immune system is running mostly on a fixed pool of memory cells. Thymalin's claim is that a short injection cycle can partially restore that function.
It's used in short cycles by injection, typically 10 days at a time, once or twice a year. You won't feel anything during the course. The case for it rests on 40+ years of Russian clinical use, a long-running cohort study showing reduced mortality in elderly patients given thymalin (often paired with the pineal peptide epithalamin), and more recently a 2021 COVID-19 trial reporting roughly halved in-hospital mortality in severe older patients when thymalin was added to standard care. Western randomised trials in healthy adults are essentially absent. People take it as an immune reset, not something they expect to register subjectively.

Deep-dive

Thymalin sits in the same family of Khavinson short peptide bioregulators as
🧬
Epitalon
and
Pinealon
Pinealon
, but it differs in one important way. Epitalon and pinealon are single synthetic peptides (AEDG and EDR respectively). Thymalin is a mixed polypeptide preparation, a fraction extracted from calf thymus by mild acid extraction that contains multiple bioactive short peptides. The three that have been characterised and studied separately are the dipeptide KE (Lys-Glu, sold as Vilon), the dipeptide EW (Glu-Trp, sold as Thymogen), and the tripeptide EDP. Most of the proposed gene-expression mechanism traces to these short peptides binding double-stranded DNA or histones in promoter regions, similar to what's proposed for the other Khavinson bioregulators.
Thymic involution and what thymalin is trying to fix. The thymus is where bone-marrow-derived precursors mature into T-cells, learning to distinguish self from non-self. It hits peak mass in early life and shrinks roughly 3% per year through middle age, then about 1% per year afterwards, replaced progressively by fat. By the seventh decade, output of naive T-cells has dropped enormously and the T-cell pool becomes dominated by oligoclonal memory cells, less able to respond to new pathogens. This is the structural reason older people die more often from infections, respond worse to vaccines, and have higher rates of cancer. The framework called immunosenescence, with its companion process of chronic low-grade inflammation (inflammaging), is now mainstream immunology. Thymalin's pitch is that it gives the residual thymic tissue, or the broader immune compartment, a signal that recovers some of the lost function.
Gene expression and the active short peptides. A 2021 Khavinson review lays out the proposed mechanism. The KE, EW, and EDP peptides are small enough to enter cells and the nucleus, where they bind specific DNA sequences in gene promoters. KE has been shown to normalise telomere length in PHA-stimulated lymphocytes across age groups, suppress the HER-2/neu oncogene in transgenic mice by roughly half, and raise SIRT1 expression while lowering PARP1 and PARP2 in mesenchymal stem cells. EW (Thymogen) drives T-cell differentiation and shifts cytokine output toward IL-2 and interferon. EDP is the least studied of the three but is part of the activity ascribed to the whole extract. The simplest reading is that thymalin works as a small mix of complementary epigenetic signals, with each fragment hitting different gene clusters relevant to T-cell function, inflammation, and cellular aging.
Cytokine modulation. A 2023 in vitro paper tested thymalin and its KE and EW components on LPS-stimulated human peripheral blood mononuclear cells. Synthesis of IL-1β, IL-6, and TNF-α, the three cytokines that drive most chronic and acute inflammatory damage, fell by 1.4 to 6-fold. Bioinformatic analysis pointed to the AKT1/AKT2 pathway and the CHUK and ACE2 genes as likely targets. This matters because the same cytokines are central to the cytokine storm that kills severe COVID-19 patients and to the chronic inflammation that defines inflammaging.
Human mortality data. The headline number for thymalin is from a prospective cohort of 266 people over 60 run by the Khavinson group. Treatment with thymalin alone was associated with a 1.6 to 1.8-fold reduction in mortality over 6 years. Treatment with thymalin plus epithalamin (the pineal extract that epitalon was derived from) produced a 2.5-fold reduction. Annual administration of both gave a 4.1-fold reduction. The bioregulators were given for the first 2-3 years of observation and the survival benefit persisted across the full follow-up. Improvements were reported across cardiovascular, endocrine, immune, and metabolic markers. These effect sizes are extraordinary, and they're also from a single research group, were not blinded to modern RCT standards, and have never been independently replicated in the West. Treat them as a strong hypothesis, not a settled finding. The same caveat applies to thymalin as to
🧬
Epitalon
, the evidence is intriguing and consistent within the Russian program, thin everywhere else.
COVID-19. The most recent meaningful human data is the 2021 Kuznik and Khavinson trial in severe COVID-19 patients over 60. Thymalin added to standard therapy (n=36) produced faster clinical improvement, faster recovery from lymphopenia, faster normalisation of C-reactive protein and D-dimer, and roughly halved in-hospital mortality versus standard therapy alone. A separate paper from the same group tracked hematopoietic stem cell differentiation and confirmed that thymalin accelerated the decline of IL-6, CRP, and D-dimer while preserving T-cell parameters. The trial was conducted in Russia, not blinded to Western standards, and the standard of care in that setting was different from a modern Western ICU. It is the strongest acute infection signal thymalin has, and it lines up with the proposed mechanism of dampening cytokine storm while preserving adaptive immunity.
The pineal-thymic axis. Khavinson's group has repeatedly shown that thymalin and epithalamin work better together than either alone, and proposed a bidirectional regulatory axis between the pineal gland and thymus. Pineal peptides protect thymic function, and thymic peptides influence melatonin rhythm. This is part of why epitalon and thymalin are the historical pair, the mortality data is much stronger for the combination than for either alone. If you're already running cycles of one, the second one is the natural addition.
Animal evidence. The cancer story has been worked over for decades in the Khavinson program. In a 25-year program of studies on female CBA mice, thymic peptide preparations (including thymalin and its synthetic dipeptide derivative thymogen) extended lifespan and reduced spontaneous tumour incidence. In female rats exposed to Sr-90 and Cs-137, thymogen suppressed radiation-induced carcinogenesis, including breast adenocarcinoma, and extended lifespan in unexposed animals. The animal cancer evidence trends consistently in the protective direction. Most of it comes from the same institute.
Use in cancer patients. Thymalin has been used as an adjunct in Russian oncology for chemotherapy and radiotherapy-induced immune suppression. A 1985 study in 21 women with cancer of the uterine corpus reported pronounced immunomodulatory effects on T-cell immunity when thymalin was added to complex antitumour treatment. A 1991 study in disseminated cervical cancer reported similar effects. This is observational, unblinded, decades old, and from a single research tradition, but it's the use case where thymalin has the most direct human clinical track record and it's directly relevant to women.
Women. Most of the foundational animal cancer work was done in female animals, and the strongest human clinical track record outside the elderly cohort studies is in women with gynaecological cancers receiving adjunctive thymalin. There is no reason to think the immune effects differ meaningfully by sex, and no dose adjustment is recommended. Postmenopausal women face accelerated thymic involution alongside other immune shifts (decline in oestrogen tone, increased autoimmunity risk, faster bone and skin aging), and the rationale for a thymic restoration peptide arguably maps to that demographic at least as well as it does to men. The trial data to back this up specifically is the elderly mortality cohort which included both sexes without stratifying. Skip in pregnancy and breastfeeding, no human safety data exists in either.
Limitations of the evidence. Almost all of the foundational work is from a single institute and is published largely in Russian. The proposed gene expression mechanism is plausible but not definitively established. The cohort studies are unblinded and non-randomised. There is no Western-standard randomised controlled trial of thymalin in any indication. The active peptide composition of natural thymalin varies from batch to batch because it's a mixed extract rather than a single synthetic molecule, which is a real issue for reproducibility and for evaluating what's actually in any given vial. The synthetic single-peptide alternatives (thymogen for EW, vilon for KE) are characterised and reproducible but only cover part of what's in thymalin. The peptide is also widely sold as a research chemical with highly variable purity. Treat the strong-sounding human numbers with appropriate skepticism, the mechanism is interesting, the long-running clinical signal is consistent, the evidence base is thin by international standards.

Dosage:

  • Standard cycle: 10 mg per day, subcutaneous or intramuscular, for 10 consecutive days. This is the protocol used in the Russian clinical work, the COVID-19 trial, and the longevity cohort studies. It's the de facto community standard
  • Cycling: the protocol is intermittent, not continuous. Most users run a cycle once or twice a year. Twice yearly (e.g. spring and autumn) mirrors the schedule that produced the strongest mortality reduction in the Khavinson cohort. Daily indefinite use is not supported by any of the trials and the proposed mechanism is consistent with intermittent dosing leaving lasting effects after the peptide clears
  • Maintenance / first-time users: 5 mg daily for 5-10 days is a reasonable lower-end starting cycle. The dose-response is fairly flat above 10 mg, doubling the dose doesn't double the effect, so there's no reason to push higher
  • Reconstitution: bacteriostatic water. Because thymalin is a mixed extract and lacks a synthetic stabiliser, reconstituted solution is less stable than for single-peptide preparations. Refrigerate and use within 7-14 days. Some practitioners reconstitute the daily dose fresh each day from individual vials
  • Injection site: subcutaneous in abdominal fat is the easiest. Intramuscular (glute or deltoid) is the more traditional Russian clinical route and may be more comfortable given the volume. Rotate sites across the cycle
  • Timing within the day: morning is standard. There's no stimulant effect so evening is acceptable, and some practitioners prefer evening dosing because of the proposed pineal-thymic axis interaction. Pick one and stay consistent
  • Oral, sublingual, and nasal forms: sold but the absorption case is weak. The injection protocol is what every meaningful trial has used and what the dose recommendations are based on. If you are not going to inject, expect a much smaller effect
  • Stacks: the natural pair is
    🧬
    Epitalon
    , which is what the strongest mortality data combined it with. Run them as parallel cycles, either together for the full 10 days or staggered, depending on whether you want a single intensive course or spread the injection burden. Also complements
    Pinealon
    Pinealon
    in the broader Khavinson framework. For non-Khavinson stacks, doesn't overlap mechanistically with NAD+ precursors, spermidine, or other autophagy/mitochondrial-focused longevity tools, you can add it to those without redundancy. The synthetic single-peptide derivatives, Thymogen (Glu-Trp, the EW dipeptide isolated from thymalin) and Vilon (Lys-Glu, the KE dipeptide), are sold separately and cover part of thymalin's activity at lower cost. No dedicated pages yet, worth adding.
  • Women specifically: no dose adjustment. Same 10 mg daily x 10 days, once or twice yearly. Skip during pregnancy and breastfeeding

Here's what you can expect:

During the cycle itself, most people notice nothing acute. Thymalin doesn't produce a felt effect the way a stimulant, anxiolytic, or growth hormone secretagogue does. A subset of users report subtle changes within or shortly after a course: faster recovery from a cold or other infection that happened to coincide with the cycle, slightly steadier energy, sometimes a vague sense of resilience. These are anecdotal, inconsistent across people, and not the primary endpoint.
The more measurable effects, if they happen, show up in immune markers over weeks to months: a shift in T-cell counts and CD4/CD8 ratio, reduced inflammatory markers (hs-CRP, IL-6), better response to vaccines, fewer respiratory infections through the following season. The Khavinson cohort tracked these and reported normalisation toward younger ranges. None of this is going to be obvious from the inside.
The real bet is the long-horizon claim, that running yearly or biannual cycles slowly shifts your risk curve on the infection, cancer, and cardiovascular endpoints the Russian cohorts measured. You cannot verify that in an individual within a single cycle.

Side effects & risks:

  • Generally well tolerated across 40+ years of Russian clinical use. No serious adverse events were reported in the multi-year cohort work, the COVID-19 trial, or the oncology adjunct studies at the standard dose
  • Injection site reactions (redness, mild swelling, transient soreness) are the most common practical issue. Rotate sites and use sterile technique
  • Mild flu-like symptoms (transient fatigue, low-grade temperature, mild myalgia) occasionally occur in the first days of a cycle, consistent with immune activation. Usually resolves as the course continues
  • Autoimmune conditions: caution. Thymalin upregulates T-cell function and shifts cytokine balance, which is the goal in immunosenescence but is the wrong direction in active lupus, MS, RA, Hashimoto's, or other active autoimmune disease. Avoid during active flares. If autoimmune disease is stable on treatment, discuss with a clinician before starting
  • Active or recent cancer: the Russian oncology data trends protective rather than harmful, but the evidence is from adjunctive use under oncology supervision, not from self-administration in undiagnosed disease. If you have an active or recent malignancy, do not start thymalin without clinician oversight
  • Organ transplant recipients on immunosuppression: avoid. Immune stimulation can interfere with the transplant tolerance the immunosuppressants are maintaining
  • Pregnancy and breastfeeding: skip. No human safety data
  • Children and adolescents: not enough data outside the Russian paediatric clinical use case (which was specific to immunodeficiency in supervised settings). Not appropriate for healthy children or adolescents whose thymus is still functioning normally
  • No established drug interactions in the published literature, but the evidence base is thin enough that interactions with biologics, immunosuppressants, or chemotherapy regimens cannot be ruled out. If you are on any of these, get clinician input before starting
  • Source quality is the single biggest practical risk. Thymalin is a mixed natural extract, which makes batch-to-batch variability inherent to the product even at the official Russian pharmaceutical grade. In the research chemical market, what is sold as thymalin may be a different extract, a degraded preparation, or in some cases the synthetic single dipeptide (thymogen) relabelled. Source from vendors that publish third-party analytical testing for each batch. If you are going to inject this, reconstitute with bacteriostatic water using sterile technique
  • Long-term safety data in healthy adults is limited. The cohort studies were in elderly people. Running yearly cycles from your 30s or 40s for decades is unexplored territory

🩸

Blood markers

Full immune panel (CBC with differential, total lymphocyte count, CD4/CD8 ratio, NK cell count), baseline before starting. Recheck 4-6 weeks after the cycle if you want to see whether your immune profile actually shifted. The Khavinson studies tracked these as the primary readouts and they're the most direct way to assess effect.
hs-CRP, IL-6, fibrinogen, baseline and post-cycle. Thymalin's main inflammatory effect is downward, and these are the markers most likely to register the change. Elevated baseline values in someone otherwise healthy is a stronger indication that a course might do something.
Standard longevity panel, baseline and annual: HbA1c, fasting glucose and insulin, full lipid panel including ApoB, eGFR, ALT/AST. The Russian cohort studies tracked cardiovascular and metabolic endpoints alongside immune endpoints, and watching these is the practical way to assess broader effect.
Thyroid panel (TSH, free T4, free T3) and autoantibodies (anti-TPO, anti-Tg), baseline. Autoimmune thyroid disease is the most common occult autoimmune condition in adults, especially women, and is the contraindication most likely to be missed. If anti-TPO or anti-Tg are elevated, reconsider whether thymalin is appropriate.
For someone using thymalin once or twice yearly without specific health concerns, an annual immune and longevity panel plus a thyroid check is sufficient. More frequent testing only makes sense if you are tracking response to a specific condition.
Sold as a research chemical or laboratory peptide in most jurisdictions outside Russia, where it has been an approved prescription medicine since 1982.